The impact of a programme to improve quality of care for people with type 2 diabetes on hard to reach groups: The GEDAPS study
Danielle H Bodicoat, Xavier Mundet, Melanie J Davies, Kamlesh Khunti, Pilar Roura, Josep Franch, Manel Mata-Cases, Xavier Cos, J Franciso Cano
Primary Care Diabetes | ELSEVIER SCI LTD | Published : 2015
The GEDAPS group Continuous Quality Improvement Programme has received financial support from Bayer, Novo Nordisk, GlaxoSmithKline, Merck Sharp & Dhome Spain, Sanofi Aventis, Novartis Pharmaceuticals, Menarini Diagnostics and the Fundacio d'Atencio Primaria. DHB received a Santander Travel Award to conduct this work. DHB, MJD and KK acknowledge support from the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care - East Midlands (NIHR CLAHRC - EM), the Leicester Clinical Trials Unit and the NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity Biomedical Research Unit which is a partnership between University Hospitals of Leicester NHS Trust, Loughborough University and the University of Leicester. The funders had no role in the study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit for publication.